For instance, the maintenance of basal levels of cathepsin B supports the investigation of Pt(IV)-based prodrugs in combination with cathepsin modulators, which may positively impact the efficacy of the treatments by additional reduction of the proliferative potential of GBM cells. This evidence concerns the gene CTSS and glioblastoma.